Raul Gainetdinov (born September 1, 1964) is a pharmacologist and neuroscientist. The main direction of his research is psychiatric and neurological diseases of the brain, such as schizophrenia, ADHD, depression and Parkinson's disease. He is the author of fundamental scientific works in pharmacology of dopamine,[1]β-Arrestins[2][3] and NMDA receptors.[4] He is a pioneer researcher of Trace amine-associated receptors.[5][6][7]
Since 2015 Director of Institute of Translational Biomedicine[10] and Head of Laboratory of Neuroscience and Molecular Pharmacology, Saint Petersburg State University.[12]
Influence
Since 2018 Raul Gainetdinov has been included in the Web of Science Highly Cited Researchers list.[13][14]h-index 82.[15]
^Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT (1999-12-24). "Enhanced Morphine Analgesia in Mice Lacking β-Arrestin 2". Science. 286 (5449): 2495–2498. doi:10.1126/science.286.5449.2495. PMID 10617462.
^Mohn AR, Gainetdinov RR, Caron MG, Koller BH (1999-08-20). "Mice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia". Cell. 98 (4): 427–436. doi:10.1016/S0092-8674(00)81972-8. PMID 10481908.
^Premont RT, Gainetdinov RR, Caron MG (2001-08-14). "Following the trace of elusive amines". Proceedings of the National Academy of Sciences. 98 (17): 9474–9475. Bibcode:2001PNAS...98.9474P. doi:10.1073/pnas.181356198. PMC 55475. PMID 11504935.